Cargando…

Cell-free DNA in newly diagnosed patients with glioblastoma – a clinical prospective feasibility study

Background: Glioblastoma (GB) is an incurable brain cancer with limited treatment options. The aim was to test the feasibility of using cell-free DNA (cfDNA) to support evaluation of treatment response, pseudo-progression and whether progression could be found before clinical and/or radiologic progr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nørøxe, Dorte Schou, Østrup, Olga, Yde, Christina Westmose, Ahlborn, Lise Barlebo, Nielsen, Finn Cilius, Michaelsen, Signe Regner, Larsen, Vibeke Andrée, Skjøth-Rasmussen, Jane, Brennum, Jannick, Hamerlik, Petra, Poulsen, Hans Skovgaard, Lassen, Ulrik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2019
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6633897/ https://www.ncbi.nlm.nih.gov/pubmed/31320993 http://dx.doi.org/10.18632/oncotarget.27030

Ejemplares similares

Tumor mutational burden and purity adjustment before and after treatment with temozolomide in 27 paired samples of glioblastoma: a prospective study
por: Schou Nørøxe, Dorte, et al.
Publicado: (2021)

Genomic profiling of newly diagnosed glioblastoma patients and its potential for clinical utility – a prospective, translational study
por: Nørøxe, Dorte S., et al.
Publicado: (2020)

Extracranial metastases in glioblastoma—Two case stories
por: Schou Nørøxe, Dorte, et al.
Publicado: (2018)

Detection of copy number alterations in cell-free tumor DNA from plasma
por: Østrup, Olga, et al.
Publicado: (2017)

Targeting glioma stem‐like cell survival and chemoresistance through inhibition of lysine‐specific histone demethylase KDM2B
por: Staberg, Mikkel, et al.
Publicado: (2018)

Hallmarks of glioblastoma: a systematic review
por: Nørøxe, Dorte Schou, et al.
Publicado: (2017)

Plasma total cell-free DNA is a prognostic biomarker of overall survival in metastatic solid tumour patients
por: Viller Tuxen, Ida, et al.
Publicado: (2019)

Circulating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumors
por: Ahlborn, Lise Barlebo, et al.
Publicado: (2018)

The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients
por: Poulsen, Hans Skovgaard, et al.
Publicado: (2014)

VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance
por: Michaelsen, Signe R, et al.
Publicado: (2018)

Clinical Characteristics of Gliosarcoma and Outcomes From Standardized Treatment Relative to Conventional Glioblastoma
por: Frandsen, Simone, et al.
Publicado: (2019)

Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma
por: Urup, Thomas, et al.
Publicado: (2020)

Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patients
por: Urup, Thomas, et al.
Publicado: (2017)

Combined EGFR- and notch inhibition display additive inhibitory effect on glioblastoma cell viability and glioblastoma-induced endothelial cell sprouting in vitro
por: Staberg, Mikkel, et al.
Publicado: (2016)

(18)F-FET MicroPET and MicroMRI for Anti-VEGF and Anti-PlGF Response Assessment in an Orthotopic Murine Model of Human Glioblastoma
por: Nedergaard, Mette Kjoelhede, et al.
Publicado: (2015)

VEGF-C as a putative therapeutic target in cancer
por: Michaelsen, Signe R., et al.
Publicado: (2019)

Application of cell-free DNA for genomic tumor profiling: a feasibility study
por: Ahlborn, Lise B., et al.
Publicado: (2019)

Neoepitope load, T cell signatures and PD-L2 as combined biomarker strategy for response to checkpoint inhibition immunotherapy
por: Borch, Annie, et al.
Publicado: (2023)

Systemic Immune Modulation in Gliomas: Prognostic Value of Plasma IL-6, YKL-40, and Genetic Variation in YKL-40
por: Holst, Camilla Bjørnbak, et al.
Publicado: (2020)

ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling – a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial
por: Kringelbach, Tina, et al.
Publicado: (2023)

DNA Methylation Levels of the ELMO Gene Promoter CpG Islands in Human Glioblastomas
por: Michaelsen, Signe Regner, et al.
Publicado: (2018)

Plasma IL-8 and ICOSLG as prognostic biomarkers in glioblastoma
por: Holst, Camilla Bjørnbak, et al.
Publicado: (2021)

Clinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme: an observational study of a cohort of consecutive non-selected patients from a single institution
por: Michaelsen, Signe Regner, et al.
Publicado: (2013)

Actionable Molecular Alterations Are Revealed in Majority of Advanced Non-Small Cell Lung Cancer Patients by Genomic Tumor Profiling at Progression after First Line Treatment
por: Frank, Malene Støchkel, et al.
Publicado: (2021)

High frequency of pathogenic germline variants within homologous recombination repair in patients with advanced cancer
por: Bertelsen, Birgitte, et al.
Publicado: (2019)

A Prognostic Model for Glioblastoma Patients Treated With Standard Therapy Based on a Prospective Cohort of Consecutive Non-Selected Patients From a Single Institution
por: Abedi, Armita Armina, et al.
Publicado: (2021)

SPT6-driven error-free DNA repair safeguards genomic stability of glioblastoma cancer stem-like cells
por: Obara, Elisabeth Anne Adanma, et al.
Publicado: (2020)

Detection of circulating tumor-derived material in peripheral blood of pediatric sarcoma patients: A systematic review
por: Kjær, Eva Kristine Ruud, et al.
Publicado: (2023)

Redefining germline predisposition in children with molecularly characterized ependymoma: a population-based 20-year cohort
por: Foss-Skiftesvik, Jon, et al.
Publicado: (2022)

Fractionated palliative thoracic radiotherapy in non-small cell lung cancer – futile or worth-while?
por: Støchkel Frank, Malene, et al.
Publicado: (2018)

The Use of Longitudinal (18)F-FET MicroPET Imaging to Evaluate Response to Irinotecan in Orthotopic Human Glioblastoma Multiforme Xenografts
por: Nedergaard, Mette K., et al.
Publicado: (2014)

Perspective: targeting VEGF-A and YKL-40 in glioblastoma – matter matters
por: Holst, Camilla Bjørnbak, et al.
Publicado: (2021)

Maternal versus paternal inheritance of a 132 bp 11p15.5 microdeletion affecting KCNQ1OT1 and associated phenotypes
por: Stoltze, Ulrik Kristoffer, et al.
Publicado: (2023)

A Comparison of Tools for Copy-Number Variation Detection in Germline Whole Exome and Whole Genome Sequencing Data
por: Gabrielaite, Migle, et al.
Publicado: (2021)

Implementing targeted therapies in the treatment of glioblastoma: Previous shortcomings, future promises, and a multimodal strategy recommendation
por: Fougner, Vincent, et al.
Publicado: (2022)

Early, Patient-Centered, and Multidisciplinary Approach in Newly Diagnosed Multiple Myeloma: What Are We Talking About? A Case Description and Discussion
por: Sørensen, Jonas, et al.
Publicado: (2022)

BRCA1-regulated RRM2 expression protects glioblastoma cells from endogenous replication stress and promotes tumorigenicity
por: Rasmussen, Rikke D., et al.
Publicado: (2016)

Author Correction: BRCA1-regulated RRM2 expression protects glioblastoma cells from endogenous replication stress and promotes tumorigenicity
por: Rasmussen, Rikke D., et al.
Publicado: (2018)

A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON study
por: Eriksen, Martina, et al.
Publicado: (2022)

Timing of Early Postoperative MRI following Primary Glioblastoma Surgery—A Retrospective Study of Contrast Enhancements in 311 Patients
por: Rykkje, Alexander Malcolm, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_e5pmgs59n5a6glgisla2t01kh4